On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion
Revenue from operations climbed 13% to Rs. 886.87 crore
New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain
The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030
Company enters women’s personal grooming segment while strengthening pain management portfolio with herbal Ortho Oil
We are building an AI-native operating system for pharma sales and distribution
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
